Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly

Journal of Endocrinological Investigation

Volumn 23, Issue 1, 2000, Pages 12-18

  Wasko R ^a   Ruchalla M ^a   Sawicka, J ^a   Kotwicka, Malgorzata ^a   Liebert, W ^a   Sowinski J ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acromegaly; Hypophyseal adenoma; Somatostatin analogues

Indexed keywords

ALPHA1 GLYCOPROTEIN; ANGIOPEPTIN; FOLLITROPIN; GROWTH HORMONE; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; THYROTROPIN;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS ADENOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PREOPERATIVE TREATMENT; PROLACTIN BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; TUMOR VOLUME;

EID: 2542507865     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343669     Document Type: Article

References (34)

1. Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Liuzzi A., Chiodini P.G. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly. Clin. Endocrinol. Metab. 1986, 62: 601-604.
2. Grossman A., Ross R., Wass J.A.H., Besser G.M. Depot bromocriptine treatment for prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 1986, 24: 231-238.
3. Lamberts S.W.J., Klijn J.G.M., Van Vroonhoven C.C.J., Stefanko S.Z. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyreotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH (prolactin-containing pituitary adenomas). J. Clin. Endocrinol. Metab. 1985, 60: 1148-1153.
4. Ferrari C., Paracchi A., Romano C., Gerevini G., Boghen M., Barreca A., Fortini P., Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 1988, 29: 467-476.
5. Abs R., Verhelst L., Maiter D., Van Acker K., Nobels F., Coolens J.L., Mahler C. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 1998, 83: 374-378.
6. Muratori M., Arosio M., Gambino G., Romano C., Blella O., Faglia G.J. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patient. J. Endocrinol. Invest. 1997, 20: 537-546.
7. Jackson S.N., Fowler J., Howlett T.A. Treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 1997, 46: 745-749.
8. Lombardi G., Colao A., Ferone D., Sarnacchiaro F., Marzullo P., Di Sarno A., Rossi E., Merola B. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur. J. Endocrinol. 1995, 132: 559-564.
9. Colao A., Lombardi G. Growth-hormone and prolactin excess. Lancet 1998, 352: 1455-1461.
10. Carvalho D., Barbosa A., Freitas P., Machado-Carvalho A., Baldaque-Faria A., Cruz J., Pina R., Cruz C., Medina J. Preoperative octreotide treatment of acromegaly. J. Endocrinol. Invest. 1996, 19 (Suppl. 5): 12.
11. Ezzat S., Snyder P.J., Young W.F. Octreotide treatment of acromegaly. A randomized, multicenter study. Arch. Intern. Med. 1992, 151: 711-718.
12. Ezzat S., Kontogeorges G., Redelmeier D.A., Horvath E., Harris A.G., Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomasto octreotide. Eur. J. Endocrinol. 1995, 132: 686-690.
13. Pompili A., Carapella C.M., Crecco M., Mottolese M., Nardone M.R., Occhipinti E., Rocco A., Tofani A. Presurgical treatment with octreotide in pituitary adenomas. J. Endocrinol. Invest. 1996, 19: 26.
14. Sassolas G. Medical therapy with somatostatin analogues for acromegalyc. Eur. J. Endocrinol. 1995, 133: 675-677.
15. Barkan A.L., Lloyd R.V., Chandler W.F., Hatfield M. K, Gebarski S.S., Kelch R.P., Beitins I.Z. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J. Clin. Endocrinol. Metab. 1988, 67: 1040-1048.
16. Melmed S. Medical management of acromegaly - what and when? Acta Endocrinol. (Copenh.) 1993, 129 (Suppl. 1): 13-17.
17. Colao A., Ferone D., Cappabianca P., del Basso De Caro M.L., Marzullo P., Monticelli A., Alfieri A., Merola B., Calì A., de Divitiis E., Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. J. Clin. Endocrinol. Metab. 1997, 82: 3308-3314.
18. Lamberts S.W., Reubi J.C., Krenning E.P. Somatostatin analogs in the treatment of acromegaly. Endocrinol. Metab. Clin. North Am. 1992, 21: 737-752.
19. Newman C.B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molith M.E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M.L., Barkan A., Frohman L., Kleinberg D.L. Octreotide as primary therapy for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83: 3034-3040.
20. Lucas Morante T., Garcia Uria L., Estrada J., Saucedo G., Cabello A., Alcañiz J., Barceló B. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J. Neurosurg. 1994, 81: 10-14.
21. Fahlbusch R., Honegger J., Buchfelder M. Acromegaly - the place of the neurosurgeon. Metabolism 1996, 45: 65-66.
22. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur. J. Endocrinol. 1995, 132: 320-325.
23. Papi G., Magnoni I., Pesenti M., Gola M., Tavernani V., Velardo A. Efficacy of delayed release lanreotide in the medical therapy of acromegaly. Minerva Endocrinol. 1998, 23: 57-63.
24. Hoyer D., Bell G.I., Berelowitz M., Epelbaum L., Feniuk W., Humphrey P.P.A., O'Carroll A.M., Patel Y.C., Schonbrunn A., Taylor J.E., Reisine T. Classification and nomenclature of somatostatin receptors. Elsevier Science Ltd-TiPS 1995, 16: 86-88.
25. Viollet C., Prevost G., Maubert E., Faivre-Bauman A., Gardette R., Kordon C., Loudes C., Slama A., Eperbaum J. Molecular pharmacology of somatostatin receptors. Fundam. Clin. Pharmacol. 1995, 9: 107-113.
26. Marek L., Hana V., Krsek M., Justova V., Catus F., Thomas C. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 1994, 131: 20-26.
27. Andrieu J.M., Renard E., de Boisvilliers F., Seignarbieux F., Kerr C., Frerebeau P., Bringer J., Jaffiol C. Somatostatin analogues as primary or secondary treatment of acromegaly: evaluation of efficacy on GH suppression and side effects as surgery and radiotherapy J. Endocrinol. Invest. 1996, 19 (Suppl. 5): 23.
28. Stevenaert A., Harris A.G., Kovacs K. Presurgical octreotide treatment in acromegaly. Metabolism 1992, 41: 51-58.
29. Giusti M., Ciccarelli E., Dallabonzana D., Deitalla G., Faglia G., Liuzzi A., Gussoni G., Giordano Disem G. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur. J. Clin. Invest. 1997, 27: 277-284.
30. Gancel A., Vuillermet P., Legrand A., Calus F., Thomas F., Kuhn J.M. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenom. Clin. Endocrinol. (Oxf.) 1994, 40: 421-428.
31. Colao A., Ferone D., Lastoris S., Cerbone G., Di Saron A., Longobardii S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 1996, 81: 2356-2362.
32. Chanson P. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? Eur. J. Endocrinol. 1997, 136: 359-361.
33. Zgliczyñski W., Soszyñski P., Jeske W., Zgliczyñski S. Effects of the long-acting somatostatin analog (somatuline) on blood glucose homeostasis in acromegaly. J. Endocrinol. Invest. 1996, 19 (Suppl.): 23-25.
34. Kuhn J.M., Basin C., Mollard M., De Rouge B., Schatz B., Wolf L.M. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostatis in normal men. Eur. J. Clin. Invest. 1992, 22: 793-799.